PATENT CLAIM ANALYSIS

Application Number: 15899842
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["544", "331000"]

Abstract:
The present disclosure relates to azetidine compounds. The azetidine compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The present disclosure furthermore relates to the use of azetidine compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

Claim (Index 21):
The pharmaceutical composition or kit according to  claim 20 , wherein the at least one DPP-IV inhibitor is selected from the group consisting of alogliptin, linagliptin, saxagliptin, sitagliptin, anagliptin, teneligliptin, trelagliptin, vildagliptin, gemigliptin, omarigliptin, evogliptin and dutogliptin.

Metadata:
- Claim Count in Document: 128.0
- Percentile: 88.0
- Lexical Diversity: 1.5
- Patent Class: 544.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15284213', '15284334', '14048425', '15301603', '15039607']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7778928241129156
- 35 USC 102 Novelty (BERT): 0.4994361592404838
- Combined Prediction Score: 0.7500471576256724
- Mean Citation Score: 240.448416
- Max Citation Score: 281.36795
- Similarity Product: 250.46429565109608

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test